Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Sep
Source: Bse
Alkyl Amines Chemicals Limited (ALKYLAMINE)
Micro CapChemicals stocks · Micro cap · NSE
Alkyl Amines Chemicals Limited manufactures aliphatic amines and specialty chemicals. The company serves diverse end-user industries including pharmaceuticals, agrochemicals, rubber chemicals, water treatment, and electronic chemicals.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals14 Oct 2026 · screener
Latest result04 Aug, 08:07 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags15 Aug 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Chemicals P/E 32.2 (n=45)
Technical timing lens
Trend score and candlestick chart
41NeutralSMA20 -6.8% / mo · MACD − · sector -5.7pp vs Nifty 500 (3M)
Stock trend: 43
Sector RS: 39
Sector 3M: -11.3% vs Nifty 500 -5.6%
Chemicals FPI tailwindBuilding
Latest FPI flow is positive, but a second consecutive positive fortnight is still required. View sector evidence
Technical chart
ALKYLAMINED candles · FIT view+12.1%Latest close ₹1721.40 on 2026-10-21
Bar
-4.4%
RSI
38
MACD hist
-4.02
52W pos
56%
2026-10-21O ₹1800.00H ₹1800.00L ₹1706.00C ₹1721.40Vol 44,473 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
ALKYLAMINENifty ChemicalsNifty 500
- ALKYLAMINE
- -6.3%
- Nifty 500
- -6.5%
- Nifty Chemicals
- -12.2%
- Vs Nifty 500
- +0.2 pp
Chart stats
21 Oct 2026- From 52W high
- -18.6%
- 52W range position
- 56%
- ATR (14)
- 4.4%
- Volume vs 20D
- 0.22x
- Avg traded value
- ₹38.5 Cr
- 20D price channel
- ₹1,706 - ₹2,057.3
₹2,115
₹1,212 - ₹2,115
₹74.9
Latest completed session
20-session average
56.1% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend argues for patience, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · UNDERVALUED65
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent100
Revenue +30.1% · PAT +93.9% YoY
Technical
Neutral41
Price trend and sector-relative-strength timing.
Valuation
Legacy model+3.1%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence80
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 100/100Rev +30% YoY · PAT +94% YoY · margin expansion · +36% QoQ · operating leverage
Filed 04 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹528 Cr | +30.1% | +36.4% |
| EBITDA | ₹134 Cr | +74.0% | +88.7% |
| Operating margin | 25.0% | +600 bps | +700 bps |
| PAT | ₹95 Cr | +93.9% | +111.1% |
| PAT margin | 18.0% | +592 bps | +636 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 49.50
- P/B
- 17.49
- EV/EBITDA
- 33.37
- Market Cap
- 9390.00Cr
Profitability
- ROE
- 41.40%
- ROCE
- 41.30%
- ROA
- 25.67%
- Dividend Y
- 0.54%
Growth (CAGR)
- Revenue 5Y
- 16.00%
- EPS 5Y
- 33.00%
- Revenue 3Y
- 26.00%
- EPS 3Y
- 54.00%
Balance Sheet
- Debt/Equity
- 0.16
- Interest Coverage
- 25.70×
- Altman Z
- 9.54
- Book Value
- 105.00
Cash Flow
- FCF Yield
- 1.57%
- FCF Positive Y
- 8/5
- OCF
- 188.00 Cr
- EPS TTM
- 39.47
Shareholding
- Promoter Hold
- 72.04%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 69%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 528+36.4% vs prev
Net Profit
₹ CrLatest: 95.0+111.1% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term uptrend intact. RSI 38.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~7.3% over last month) — short-term momentum negative.
- RSI(14) at 38 — falling, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 19% off 52W high · 42% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
64
RS percentile
Stage 1 Base / Transition
1M return
-7.8%
3M return
-6.3%
6M return
+12.9%
1Y return
-9.6%
RS 1D
-3
RS 20D
0
Sector rank
#14
Industry rank
#44
Stage evidence
- Price is within 1.5% of the 30-week proxy.
- The 30-week proxy changed +3.5% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price above
Sector
weakening
Industry
weakening
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 92.63-2.85%
RS vs Nifty 50093
Valuation & peers
U-Score 65 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 65 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Premium Compounder
Fundamental score breakdown
U band · UNDERVALUEDValuation2/30
Growth21/25
Quality20/20
Balance Sheet10/15
Cash Flow7/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
65
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
65/100 · legacy band UNDERVALUED
Positive drivers
- Piotroski is strong at 8/9.
- Quality contributes 20/20 to the score.
- Growth contributes 21/25 to the score.
Main drags
- Valuation is weaker at 2/30; verify the latest quarterly trend.
- Balance sheet is weaker at 10/15; verify the latest quarterly trend.
- Cash flow is weaker at 7/10; verify the latest quarterly trend.
Sector valuation model
Cyclical valuation: normalized earnings, not just trailing PE
Cyclical companies can look cheapest near peak profits, so IndiaPulse flags value-trap risk separately.
Primary lens
Mid-cycle PE/EV/EBITDA using multi-year average margins or earnings.
Secondary checks
Current margin versus 5-year average, balance sheet strength, commodity cycle.
Main risk check
A low trailing PE may mean peak-cycle earnings, not true cheapness.
PE
49.5
PB
17.5
EV/EBITDA
33.4
ROE
41.4%
ROCE
41.3%
FCF Yield
1.6%
Debt/Equity
0.2
MoS
+3.1%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE.
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
65
Previous: 63 (+2)
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+3.1%
Previous: -0.7%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
63
63
63
63
63
63
63
63
63
63
63
63
Factor attribution
Valuation
2+2
was 0
Modelled fair value
Graham Number
₹305.37
-463.7% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹1,776.15
+3.1% MoS
PEG
1.20
Comparable companies
Peers
Business-comparable peers in Chemicals — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
BALAMINES
Micro
Balaji Amines Limited
Specialty Chemicals
match 161
25
30.5
8.7%
-574%
OVERVALUED
JUBLINGREA
Large
Jubilant Ingrevia Limited
Specialty Chemicals
match 160
51
32.0
9.5%
+28%
FAIR VALUE
CLEAN
Large
Clean Science and Technology Limited
Specialty Chemicals
match 155
39
37.3
15.3%
-254%
WATCHLIST
AETHER
Micro
Aether Industries Limited
Specialty Chemicals
match 151
29
94.9
9.7%
-175%
OVERVALUED
ANURAS
Large
Anupam Rasayan India Limited
Specialty Chemicals
match 150
25
77.4
5.5%
-61%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis under stressReviewed 2026-06-08T07:08:54.396Z
Management commentary snapshot
FY26 top line and bottom line remained flat YoY, with Q4 operations facing challenges due to ammonia sourcing disruptions and raw material price volatility.
FY26 performance was flat, impacted by raw material price volatility and increased competition in methylamines. While management expects margin improvement and volume growth, geopolitical uncertainty and overcapacity in a key product segment pose ongoing challenges.
Current business mix
Sales by End-User Industry
Latest issuer-disclosed distribution across 3 reported categories.
Pharma55.0%
Agro17.5%
Other27.5%
Growth engines
Acetonitrile Demand
We are optimistic that in acetonitrile and peptides, there will be some volume growth.
Peptides Segment
There is still a lot of optimism, a lot of talk about growth, but most of it has to still materialize. It's a great addition to the acetonitrile market.
New Product Development
Products which we are already launching, which will probably come into the market in July, are also from our R&D pipeline.
Capacity and execution
Kurkumbh Project Commissioning
The project will probably be commissioned at the beginning of the next quarter (Q1 FY27). Mechanical completion is going to be completed somewhere at the end of June.
Existing Product Capacity
We have enough capacity for the next few years without having to invest anything more in the existing product capacities.
Tailwinds
Reduced Chinese Aggression
We have seen over the last quarter, a reduction in the aggressiveness of the Chinese, and we hope it will continue.
Antidumping Duty on Acetonitrile
We got the benefit of that antidumping duty towards the end of the year, leading to some improvement in our pricing.
Pharma Industry Demand
The pharma has always been a little optimistic. They were exempt from most of these tariffs.
Headwinds
Raw Material Price Volatility
The immediate impact of the war has been that the prices have risen both of our raw materials.
Ammonia Sourcing Disruption
We had a few challenges in March in operations, but we have, by and large, overcome it.
Methylamine Overcapacity
There is an overhang of capacity because a new player has come in. Aarti has also commissioned their plant.
Risk radar
Geopolitical Uncertainty
The future remains a little uncertain as long as the war continues, which we hope will get resolved soon.
Demand Destruction from High Prices
It is a bit difficult to predict whether this will have an impact on the demand. Currently, we haven't seen it because it's too early.
Competition in Methylamines
Now that we have 4 players in methylamine in the country, we expect there will be competition.
Monsoon Impact on Agro Demand
There is a little bit of concern that agro could be affected, not pharma as much as agro because they expect this monsoon also with the El Nino.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
FY26 results are compared YoY for overall annual performance. Q4 commentary highlights recent impacts of geopolitical events on raw material sourcing and prices, making QoQ relevant for sequential momentum and margin shifts.
Sector KPIs management disclosed
FY26 Volume Growth
Volume and value have been basically flat, plus-minus 1% either way; prices dropped 1% and volume probably dropped 1%.
Capacity Utilization
On an average, we must be having between 60% and 85% capacity utilization across our plants.
Ammonia Raw Material Price
Ammonia was in the region of about INR50 a kg and now we are over INR100 a kg.
Acetonitrile Product Price
Today, I think we are at about INR250 per kg. Last year's average, it came down to something like INR140, INR150.
Management forward view
Cautious Optimism
We look forward to what I would say, cautious optimism. I think we will do better than what we have over the last 3 years.
Expected Volume Growth
We expect that the next year will be like a normal year, which is about 5% to 10% growth rate.
FY27 Capex Plan
There is no major business project, just a bit of what is left over from the current new product plant at Dahej and a few engineering projects, around INR80 crores to INR90 crores.
R&D Product Disclosure Policy
We do not talk about our R&D products till the product is in the market. We announce it to the market after the plant is commissioned.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Kurkumbh Project Commissioning | Mechanical completion by end of June, commissioning in Q1 FY27. | Timely commissioning and ramp-up of the new project to contribute to revenue. |
| Raw Material Price Stabilization | Ammonia prices over INR100/kg, other RMs also rising. | Stabilization of supply chains and raw material prices, expected in 3-6 months, to reduce volatility. |
| Methylamine Capacity Utilization | Overcapacity due to new player (Aarti) commissioning plant. | Signs of market absorption of new methylamine capacity and impact on competitive intensity and margins. |
| Chinese Import Aggressiveness | Reduction in aggressiveness observed in the last quarter. | Continued reduction in Chinese imports and pricing aggression to support domestic margins. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
80Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 90th percentile of the scored universe and 85th percentile within Chemicals. Main check: results consistency is weak at 41/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
46 docs text-extracted · 37 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
90th percentile
overall median 67 · Chemicals: 85th pctile, median 73 · Micro: 81st pctile, median 73
Evidence depth
Financial-only
46 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
98
strong · capital discipline
Results
41
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 72%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 1.4%.
- ▸8 years of positive FCF.
Trust risks
- ▸1/4 latest quarters had positive YoY PAT growth.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Alkyl Amines Chemicals Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 17 Sep
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 19 Aug
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 29 Jul
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 16 Jun
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.